MONTPELLIER, France - Teva Pharmaceutical Industries  NYSE TEVA  Ltd. has announced the completion of patient enrollment for its Phase 3 trial of mdc-TJK, a potential new treatment for schizophrenia.
Teva Pharmaceutical Industries has completed patient enrollment for its Phase 3 trial of mdc-TJK, a potential new treatment for schizophrenia.